Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing number of clinical studies
3.2.1.2 Rising prevalence of cancer cases
3.2.1.3 Technological advancements in cancer contrast imaging
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and adverse reactions related to contrast agents
3.2.2.2 Presence of alternative imaging options
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Gadolinium-based contrast media
5.3 Iodinated contrast media
5.4 Radioactive agents
5.5 Other product types
Chapter 6 Market Estimates and Forecast, By Modality, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Nuclear imaging
6.3 CT scan
6.4 Mammography
6.5 MRI scan
6.6 Ultrasound
Chapter 7 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Breast cancer
7.3 Bladder cancer
7.4 Colorectal cancer
7.5 Lung cancer
7.6 Prostate cancer
7.7 Other applications
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Diagnostic centers
8.5 Other end-users
Chapter 9 Company Profiles
9.1 Bayer AG
9.2 Bracco Imaging S.p.A.
9.3 GE Healthcare Technologies Inc
9.4 Guerbet
9.5 iMAX Diagnostic Imaging
9.6 Lantheus Medical Imaging
9.7 nanoPET Pharma GmbH
9.8 Subtle Medical, Inc
9.9 Telix Pharmaceuticals Limited
9.10 Trivitron Healthcare
